Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma
Dayong Yao, Shunyao Xia, Chengjun Jin, Weiming Zhao, Wenjia Lan, Zan Liu, Youcheng Xiu
Abstract
studies identified miR-885-5p inhibition contributed to sunitinib resistance. Mechanistically, sunitinib treatment reduced GATA1 expression, which in turn reduced its binding to MIR885 promoter and resulted in miR-885-5p downregulation in transcriptional level. In addition, PLIN3 was confirmed to be directly targeted by miR-885-5p and its upregulation significantly increased lipid droplets formation to decrease sunitinib sensitivity. Therefore, GATA1/miR-885-5p/ PLIN3 pathway may serve as a potential therapeutic strategy and a biomarker for sunitinib treatment in ccRCC.
Topics & Concepts
SunitinibClear cell renal cell carcinomaDownregulation and upregulationRenal cell carcinomaCancer researchBiomarkerMedicineInternal medicineCellOncologyBiologyGeneticsBiochemistryGeneRenal cell carcinoma treatmentRenal and related cancersEpigenetics and DNA Methylation